Oncolytics Biotech Initiates Phase 2 Trial for Colorectal Cancer Treatment
Event summary
- Oncolytics Biotech has launched a Phase 2 randomized trial (REO 033) for second-line KRAS-mutant, microsatellite-stable metastatic colorectal cancer (mCRC).
- The trial will compare pelareorep, bevacizumab, and FOLFIRI against the standard bevacizumab and FOLFIRI regimen, with 30 patients per arm.
- Primary endpoint is objective response rate (ORR), with progression-free survival (PFS), overall survival (OS), safety, and biomarker analysis as secondary endpoints.
- Preliminary data from the trial is expected by the end of 2026.
- Pelareorep combination therapy previously showed median OS of 27 months and median PFS of 16.6 months in the REO 022 study, compared to 11.2 and 5.7 months, respectively, for standard-of-care therapy.
The big picture
Oncolytics Biotech is advancing its pelareorep-based immunotherapy in a critical indication for colorectal cancer, a market with significant unmet needs, particularly in younger patients. The Phase 2 trial represents a pivotal step in validating the therapy's potential to outperform standard-of-care treatments, which could position Oncolytics as a key player in the oncology space. The company's focus on strategic partnerships will be crucial in scaling its commercial impact.
What we're watching
- Clinical Efficacy
- Whether pelareorep combination therapy can replicate or exceed the compelling efficacy data from the REO 022 study in the randomized Phase 2 trial.
- Regulatory Pathway
- The pace at which Oncolytics can advance pelareorep through the Fast Track designation process for registration in second-line KRAS-mutant mCRC.
- Strategic Partnerships
- How Oncolytics will leverage potential trial success to secure partnerships for accelerated development and commercialization.
Related topics